What non-stimulant medications are used to address memory issues in ADHD? 

Non-stimulant medications such as atomoxetine, guanfacine and clonidine are often prescribed for attention deficit hyperactivity disorder (ADHD) when stimulants are not suitable or effective. According to NHS guidance, these medicines can improve attention, reduce impulsivity and support executive functioning, though their impact on memory and recall tends to be modest. Current evidence shows that non-stimulants may enhance attention and cognitive consistency, but their effects on working memory are generally smaller and less consistent than those of stimulant medications. 

When guidelines recommend non-stimulants 

Clinical guidance from the NICE NG87 guideline recommends atomoxetine or guanfacine for children and young people aged five and over who cannot tolerate stimulants such as methylphenidate or lisdexamfetamine, or when stimulants have not been effective. These medicines are also considered for people with certain health risks or contraindications, including heart conditions or significant anxiety. 

For adults, NICE advises that atomoxetine may be prescribed if stimulant medications are not suitable or cause side effects, with guanfacine generally reserved for use in specialist care. The Royal College of Psychiatrists and NHS formularies emphasise that non-stimulants should always be part of a broader care plan that includes psychoeducation, behavioural therapy and environmental adjustments rather than being used as stand-alone treatments. 

How non-stimulants affect attention, executive function and memory 

Atomoxetine, a selective noradrenaline reuptake inhibitor, increases levels of noradrenaline in brain regions that support attention and self-regulation. It typically takes several weeks to reach full effect. Studies, including a 2024 Neuroscience and Biobehavioral Reviews meta-analysis, show that atomoxetine improves attention and inhibition but produces limited improvement in working-memory tasks compared with stimulants. Nonetheless, overall executive-function gains appear comparable when used long term. 

Guanfacine and clonidine, known as alpha-2 agonists, act by enhancing prefrontal cortical function and stabilising attention. A 2023 Frontiers in Psychiatry review reported that these medicines may improve cognitive flexibility and working memory in some children, though effects are smaller and more variable than stimulants. They are sometimes chosen for children with ADHD and co-occurring tics, anxiety or sleep difficulties because they are less likely to cause overstimulation. 

Side effects and cognitive considerations 

Atomoxetine can cause nausea, sleep disturbance or mood changes, while guanfacine and clonidine can lead to tiredness or low blood pressure. According to NHS shared-care guidelines, careful monitoring and dose adjustment are essential to maintain cognitive benefits without increasing fatigue or reducing alertness. Although non-stimulants generally have a slower onset, they can offer steadier symptom control throughout the day and may help people who experience inconsistent focus or irritability with stimulant medications. For individuals exploring non-medication options, behavioural and psychological support programmes such as those developed by Theara Change can complement medical treatment by teaching practical strategies to strengthen memory and executive function. 

Key takeaway 

Non-stimulant medications like atomoxetine, guanfacine and clonidine can improve attention and certain aspects of executive functioning in ADHD, but their effects on memory recall are modest compared with stimulants. According to NICE and NHS guidance, these medicines are best used as part of a comprehensive ADHD care plan that includes psychological support, educational adjustments and behavioural strategies to help manage memory and concentration challenges effectively.

Harriet Winslow, BSc

Author

Harriet Winslow is a clinical psychologist with a Bachelor’s in Clinical Psychology and extensive experience in behaviour therapy and developmental disorders. She has worked with children and adolescents with ADHD, autism spectrum disorder (ASD), learning disabilities, and behavioural challenges, providing individual and group therapy using evidence-based approaches such as CBT and DBT. Dr. Winslow has developed and implemented personalised treatment plans, conducted formal and informal assessments, and delivered crisis intervention for clients in need of urgent mental health care. Her expertise spans assessment, treatment planning, and behavioural intervention for both neurodevelopmental and mental health conditions.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Rebecca Fernandez, MBBS

Reviewer

Dr. Rebecca Fernandez is a UK-trained physician with an MBBS and experience in general surgery, cardiology, internal medicine, gynecology, intensive care, and emergency medicine. She has managed critically ill patients, stabilised acute trauma cases, and provided comprehensive inpatient and outpatient care. In psychiatry, Dr. Fernandez has worked with psychotic, mood, anxiety, and substance use disorders, applying evidence-based approaches such as CBT, ACT, and mindfulness-based therapies. Her skills span patient assessment, treatment planning, and the integration of digital health solutions to support mental well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewer's privacy.